+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
C

Actively Recruiting

Researchers are evaluating whether patients with hormone-receptor positive, HER2-negative early breast cancer HRHER2- eBC who have intermediate to high risk of recurrence may benefit from an initial 5-year treatment with elacestrant, with or without a CDK 46 inhibitor, followed by standard endocrine therapy ET for an additional 0 to 2.5 years. This is compared to the current standard of care ET lasting between 5 and 7.5 years, with or without CDK 46 inhibitors. The study is designed for patients identified by genomic tests like Oncotype DX and response to preoperative endocrine therapy, aiming to improve long-term survival by targeting resistance mechanisms such as ESR1 mutations. Participants are randomly assigned to one of two groups one receiving elacestrant orally for 5 years, possibly combined with ribociclib a CDK 46 inhibitor for 3 years if indicated, and the other receiving standard endocrine treatments for 5 to 10 years with optional CDK 46 inhibitors as decided by their doctor. The treatments are evaluated in a parallel study design. The trial builds on previous findings in metastatic breast cancer and early breast cancer studies exploring endocrine therapy responses and genomic risk assessments. Throughout the study, participants undergo regular clinical assessments, including tumor pathology reviews, laboratory tests, and electrocardiograms to monitor safety and treatment effects. Researchers measure outcomes such as 5-year invasive disease-free survival and other survival metrics. Participants must comply with contraception requirements and be followed for treatment adherence and safety until study completion, which is planned for up to 2033.

Age: 18Years +All GendersPhase 3
33 locations
C

Actively Recruiting

Researchers are evaluating the best neoadjuvant therapy for patients with less advanced HER2-positive early breast cancer EBC. This Phase 2 trial focuses on improving treatment outcomes by comparing trastuzumab-deruxtecan T-DXd with standard chemotherapy combined with trastuzumab and pertuzumab. The study targets patients with low to intermediate risk HER2 EBC, aiming to show higher rates of complete tumor response and excellent survival outcomes. Participants receive different treatment regimens depending on their risk group and assigned study arm. Treatments include 12 or 18 weeks of T-DXd alone or combined with standard chemotherapy, trastuzumab, and pertuzumab. After neoadjuvant treatment, post-neoadjuvant therapy with T-DXd or standard care continues for up to one year, with adjustments based on tumor response. Some patients may receive additional chemotherapy depending on residual tumor burden. During the study, participants undergo regular evaluations including tumor response assessments and safety monitoring for adverse drug reactions. Key outcomes measured are pathological complete response rate after neoadjuvant therapy and distant disease-free survival after three years. Researchers also track various survival outcomes, quality of life, and treatment-related side effects over time. Participants are followed until study completion in 2030, with detailed monitoring throughout the treatment and follow-up phases.

Age: 18Years +FEMALEPhase 2
44 locations
O

Actively Recruiting

Researchers are observing patients with documented HER2-positive, HER2-low, or HER2-ultralow unresectable or metastatic breast cancer who are receiving trastuzumab deruxtecan T-DXd treatment. The study evaluates patient-reported outcomes as well as real-world effectiveness and safety of T-DXd when used according to the approved product guidelines within routine clinical practice in Germany. Additionally, patients will be informed about using a digital healthcare application DiGA. Participants receive T-DXd treatment as part of their routine care, with no specific treatment schedule dictated by the study protocol. The study includes two groups one with HER2-positive breast cancer patients and another with HER2-low or HER2-ultralow patients, each group expected to enroll approximately 400 participants. All diagnostic and treatment decisions, including visit frequency, are managed by the treating physician. During the study, participants health and treatment progress will be tracked, including patient-reported quality of life assessments using FACT-B and FACT-G questionnaires at six months. Researchers will monitor the time from first T-DXd dose to the next treatment or death, assessed for up to 60 months. The study lasts until December 2031, with ongoing observation of real-world treatment outcomes and safety.

Age: 18Years - 130YearsAll Genders
109 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of sacituzumab govitecan-hziy SG combined with pembrolizumab compared to treatment chosen by a physician for people with triple negative breast cancer that remains after surgery and pre-surgical treatment. This phase 3 trial focuses on participants whose cancer has not been fully eliminated by prior therapies and aims to find if the experimental combination improves invasive disease-free survival. Participants are randomly assigned to one of two groups. One group receives SG intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each cycle for up to 8 cycles. The other group receives either pembrolizumab alone or pembrolizumab plus oral capecitabine as determined before randomization, also for up to 8 cycles. Treatment continues until reaching 8 cycles, disease recurrence, unacceptable side effects, physician decision, consent withdrawal, or death. During the study, participants undergo various evaluations including monitoring for invasive disease-free survival for up to 60 months and overall survival for up to 96 months. Researchers also track recurrence-free survival, distant disease-free survival, treatment side effects, laboratory abnormalities, and quality of life changes. Safety assessments occur up to 38 months after the first dose plus 30 days. This long-term follow-up helps understand the treatments impact over several years.

Age: 18Years +All GendersPhase 3
378 locations
I

Actively Recruiting

Researchers are evaluating the safety and performance of the Occlutech Atrial Flow Regulator device in patients with heart failure. This international, multicenter follow-up registry aims to identify unknown side effects and determine when this treatment is appropriate. The study focuses on patients with chronic symptomatic heart failure and monitors outcomes over a 36-month period after device implantation. Participants will receive the Occlutech Atrial Flow Regulator, which is an interatrial shunt device delivered through a catheter. Treatments and procedures follow clinical routine and device instructions, performed by experienced physicians at equipped centers. The study tracks device performance and cardiovascular events at 12, 24, and 36 months after implantation. During the study, participants will undergo assessments including vital signs, lab tests, quality of life questionnaires, ECGs, and echocardiograms. Researchers will measure major adverse cardiovascular and neurological events within one year, as well as heart function, exercise capacity, and medication changes over three years. Safety and efficacy will be closely monitored throughout the follow-up period.

Age: 18Years +All Genders
36 locations